Breaking News Instant updates and real-time market news.

WMT

Wal-Mart

$97.76

0.99 (1.02%)

, AGN

Allergan

$178.89

6.97 (4.05%)

10:31
11/29/17
11/29
10:31
11/29/17
10:31

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wal-Mart (WMT) upgraded to Sector Perform from Underperform at RBC Capital analyst Scot Ciccarelli saying the company's earnings growth will remain suppressed by a multi-year investment cycle, but it will ultimately come out as a "true competitor" to Amazon (AMZN). 2. Allergan (AGN) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying that fears about a "better Botox" from Revance (RVNC) may be overdone. 3. Domino's Pizza (DPZ) upgraded to Buy from Neutral at Nomura Instinet with analyst Mark Kalinowski citing the 21% pullback in the shares from their 52-week high closing price of $218.88 on June 26. 4. Zoetis (ZTS) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger arguing the stock can continue to outperform relative to peers as it continues to benefit from long-term secular trends, including rising livestock protein consumption and the better care of pets. 5. Steven Madden (SHOO) upgraded to Buy from Neutral at Buckingham with analyst Scott Krasik saying he has increased confidence the company will achieve fourth quarter guidance due to an acceleration in boot sales, will guide fiscal 2018 sales at least inline with its long-term sales growth, potential earnings upside from tax reform, and accretion from potential acquisitions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

WMT

Wal-Mart

$97.76

0.99 (1.02%)

AGN

Allergan

$178.89

6.97 (4.05%)

DPZ

Domino's Pizza

$184.29

12 (6.97%)

ZTS

Zoetis

$71.55

0.155 (0.22%)

SHOO

Steven Madden

$41.00

1.6 (4.06%)

  • 29

    Nov

  • 06

    Dec

  • 14

    Dec

  • 08

    Jan

  • 20

    Feb

WMT Wal-Mart
$97.76

0.99 (1.02%)

11/29/17
RBCM
11/29/17
UPGRADE
Target $96
RBCM
Sector Perform
Wal-Mart upgraded to Sector Perform at RBC Capital on investment prospects
As reported earlier, RBC Capital analyst Scot Ciccarelli upgraded Wal-Mart (WMT) to Sector Perform from Underperform and raised his price target to $96 from $92. Ciccarelli says the company's earnings growth will remain suppressed by a multi-year investment cycle, but it will ultimately come out as a "true competitor" to Amazon (AMZN). The analyst says the rating change is specifically driven by recognition of Wal-Mart's progress in upgrading its store environment and labor model as well as the vast improvements made in its e-commerce capabilities which helped generate 13 consecutive quarters of positive comps and 12 quarters of positive traffic.
11/29/17
RBCM
11/29/17
UPGRADE
RBCM
Sector Perform
Wal-Mart upgraded to Sector Perform from Underperform at RBC Capital
11/27/17
LEER
11/27/17
NO CHANGE
Target $280
LEER
Outperform
Cigna most likely acquirer of Humana in any potential transaction, says Leerink
Leerink analyst Ana Gupte notes that a Change of Control 8-K filed by Humana (HUM) suggests that the company is a possible take-out target after the Medicare Advantage Annual Enrollment Season, though the company maintains that this is a needed refresh with broader policy guidelines, rather than individually driven. The analyst sees Cigna (CI) as the most likely acquirer in any potential transaction and able to offer as much as 6% accretion in year 2 and 12% in year 3 post close. However, Anthem (ANTM) and even Wal-Mart (WMT) or Walgreens Boots Alliance (WBA) could be other dark horse acquirers, she contends. Gupte expects that Cigna would need to divest its legacy Health Spring MA assets to satisfy anti-trust regulators, with multiple possible buyers for the assets including WellCare (WCG), Aetna (AET) and Anthem. The analyst reiterates an Outperform rating and $280 price target on Humana shares.
11/27/17
KEYB
11/27/17
NO CHANGE
KEYB
Rapid erosion in physical stores may be abating, says KeyBanc
KeyBanc's research consumer team says that while online remains the key avenue for growth, the rapid erosion in physical store sales may be abating. The analyst noted that strong store checks reinforce their thesis that apparel is back, with the strongest traffic at Urban Outfitters (URBN) and lululemon (LULU). Meanwhile, Wal-Mart (WMT) was able to eschew wrist bands and had solid inventory of doorbusters, while Gap (GPS) saw strong traffic at Old Navy, they contend. Additionally, KeyBanc's team says its channel checks suggest Best Buy (BBY) continues to gain share and drove healthy traffic, while Bed Bath & Beyond (BBBY) offered slightly more aggressive, but still uninspiring, undifferentiated promotions. Moreover, they believe Conn's (CONN) maintains momentum with its credit offering, credit improvement story, and the recovery in the Hurricane Harvey impacted markets. Checks also revealed solid Beauty positioning, with Ulta Beauty (ULTA) as a winner with strong holiday positioning and good traffic on Thursday/Friday, the analysts added.
AGN Allergan
$178.89

6.97 (4.05%)

11/29/17
11/29/17
UPGRADE
Target $200

Overweight
Allergan upgraded to Overweight amid 'overdone' Botox fears at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Allergan (AGN) to Overweight from Equal Weight, saying that fears about a "better Botox" from Revance (RVNC) may be overdone. Noting that data about Revance's botulinum toxin RT002 Phase 3 trial is expected "any day now," Risinger said he thinks it could be difficult for Revance to demonstrate that RT002 is materially longer-lasting than Botox. While Risinger noted he is not predicting near-term major positive catalysts for Allergan, he thinks that the negatives have largely been priced in as the stock has pulled back 33% since July. The analyst keeps a $200 price target on Allergan, which closed Tuesday at $171.92.
11/29/17
MSCO
11/29/17
UPGRADE
MSCO
Overweight
Allergan upgraded to Overweight from Equal Weight at Morgan Stanley
11/27/17
LEER
11/27/17
INITIATION
Target $237
LEER
Outperform
Allergan resumed with an Outperform at Leerink
Leerink analyst Seamus Fernandez resumed coverage of Allergan with an Outperform rating and $237 price target, citing a fresh look at the company's emerging pipeline, which in the wake of several business issues including potential generic competition versus Restasis in 2018, appears to be almost completely absent in its current valuation.
11/27/17
LEHM
11/27/17
INITIATION
Target $31
LEHM
Overweight
Revance initiated with an Overweight at Barclays
Barclays analyst Douglas Tsao started Revance Therapeutics (RVNC) with an Overweight rating and $31 price target. The analyst does not expect the company's longer-acting toxin RT-002 to displace Allergan's (AGN) Botox in aesthetics, but he's "constructive on the opportunity assuming 6-month duration."
DPZ Domino's Pizza
$184.29

12 (6.97%)

11/28/17
11/28/17
NO CHANGE
Target $215

Buy
Domino's U.S. checks point to slow start to Q4, says Longbow
Longbow analyst Alton Stump said his talks with Domino's franchisees in the U.S. lead him to believe the fourth quarter has had a much slower start than he, and the consensus view, anticipated. He has lowered his Q4 U.S. comp sales growth estimate to 4.8% from 8.1% and cut his price target on Domino's shares to $215 from $246, but believes the recent selloff in the stock already reflects the expectation that comps slowed. Stump keeps a Buy rating on Domino's.
11/02/17
11/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Yelp (YELP) upgraded to Outperform from Sector Perform at RBC Capital with analyst Mark Mahaney saying the 5% after-market decline on lower fourth quarter outlook is not warranted since it is driven entirely by the Eat24 sale. 2. Domino's Pizza (DPZ) upgraded to Buy from Hold at Maxim with analyst Stephen Anderson saying that despite the 15% pullback in stock price, the company's fundamental trends remain solid. 3. U.S. Steel (X) upgraded to Market Perform from Underperform at Cowen with analyst Novid Rassouli telling investors the company's revitalization program has improved cost performance and driven stable financial results for two consecutive quarters. 4. FireEye (FEYE) upgraded to Buy from Neutral at Dougherty with analyst Catharine Trebnick saying FireEye reproted solid third quarter results across key financial metrics beating her estimates on sales execution, strong NX appliance refresh/renewals, endpoint sales and Mandiant services. 5. Newpark Resources (NR) upgraded to Buy from Hold at SunTrust with analyst Ken Sill saying the latest quarter did not show a hurricane related boost to mat rentals as the market expected, which should result in subsequent quarters growing from a higher base established in Q3 as well as an accretive acquisition announced this week. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/02/17
MAXM
11/02/17
UPGRADE
Target $230
MAXM
Buy
Domino's Pizza upgraded to Buy from Hold at Maxim
Maxim analyst Stephen Anderson upgraded Domino's Pizza (DPZ) to Buy from Hold and raised his price target to $230 from $220 to reflect his increased same-store-sales and unit growth forecasts. Anderson says that despite the 15% pullback in stock price, the company's fundamental trends remain solid. He views yesterday's selloff after a weak earnings report from rival Papa John's (PZZA) as an overreaction given that the problems at the company are concept-specific.
11/29/17
NOMU
11/29/17
UPGRADE
Target $201
NOMU
Buy
Domino's Pizza upgraded to Buy from Neutral at Nomura Instinet
Nomura Instinet analyst Mark Kalinowski upgraded Domino's Pizza to Buy citing the 21% pullback in the shares from their 52-week high closing price of $218.88 on June 26. The analyst keeps a $201 price target for the stock. The pizza chain closed yesterday down 1%, or $2.25, to $172.29.
ZTS Zoetis
$71.55

0.155 (0.22%)

11/29/17
MSCO
11/29/17
UPGRADE
Target $80
MSCO
Overweight
Zoetis upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Zoetis to Overweight from Equal Weight, arguing the stock can continue to outperform relative to peers as it continues to benefit from long-term secular trends, including rising livestock protein consumption and the better care of pets. The analyst, who has become more confident that Zoetis can sustain its relatively high valuation, raised his price target on the stock to $80 from $70.
11/29/17
MSCO
11/29/17
UPGRADE
MSCO
Overweight
Zoetis upgraded to Overweight from Equal Weight at Morgan Stanley
11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
11/17/17
COWN
11/17/17
NO CHANGE
Target $80
COWN
Outperform
Zoetis price target raised to $80 from $70 at Cowen
Cowen analyst Steve Scala raised his price target on Zoetis to $80 from $70 as he believes the company is well positioned in a growth industry. Scala reiterated his Outperform rating on Zoetis, citing its strong Q3 results, increased confidence in its earnings outlook with upside potential, and a favorable industry backdrop.
SHOO Steven Madden
$41.00

1.6 (4.06%)

09/18/17
WELS
09/18/17
NO CHANGE
WELS
Retail seems to be stabilizing, says Wells Fargo
Wells Fargo analyst Ike Boruchow says that while it still seems too early to call for a robust recovery in retail fundamentals, the industry does seem to be stabilizing, with Q2 sales and EPS trends generally better than Q1 across the board. Further, store traffic has improved each month since February and management teams have taken a generally upbeat tone regarding back-to-school in recent public commentary, he adds. So, with solid traffic and favorable weather during the key back-to-school selling season, the analyst believes inventories could find themselves in good shape heading into the holidays and momentum appears to be on retail's side. Boruchow points out that according to his index, PVH Corp. (PVH) continues to be the ''most loved'' retailer in his universe, followed by TJX (TJX), Canada Goose (GOOS), and Steven Madden (SHOO), while Foot Locker (FL), Fossil (FOSL), and Finish Line (FINL) are the ''least loved'' names this month.
11/01/17
ADAM
11/01/17
NO CHANGE
Target $47
ADAM
Buy
Steven Madden weakness a buying opportunity, says Canaccord
Canccord analyst Camilo Lyon said Steven Madden reported another strong quarter as its Q3 results showed continued increase in market share on the strength of its right product and superior supply chain. He noted the macro-driven weakness in boots is disappointing, but was more than offset by the strength in other categories, which he reads as evidence the company is executing well. Lyon said the weakness should be bought and he reiterated his Buy rating and $47 price target on Steven Madden shares.
11/07/17
SUSQ
11/07/17
NO CHANGE
Target $48
SUSQ
Positive
Steven Madden weakness a buying opportunity, says Susquehanna
Susquehanna analyst Sam Poser said the selloff in Steven Madden is overdone as the company met consensus in a tough operating environment. He said the company remains best-in-class in terms of speed-to-market with clean inventory that positions it for long-term profitable growth. Poser reiterated his Positive rating and $48 price target on Steven Madden shares.
11/29/17
BUCK
11/29/17
UPGRADE
BUCK
Buy
Steven Madden upgraded to Buy from Neutral at Buckingham
Buckingham analyst Scott Krasik upgraded Steven Madden to Buy and raised its price target to $48 from $38. The analyst has increased confidence the company will achieve Q4 guidance due to an acceleration in boot sales, will guide FY18 sales at least inline with its long-term sales growth, potential earnings upside from tax reform, and accretion from potential acquisitions.

TODAY'S FREE FLY STORIES

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

11:00
12/15/17
12/15
11:00
12/15/17
11:00
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark opens at $14.05,…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

EEM

MSCI Emerging Markets Index

$46.07

-0.005 (-0.01%)

11:00
12/15/17
12/15
11:00
12/15/17
11:00
Options
90K iShares Emerging Markets Fund Jun 42 puts bought for $1.04 »

90K iShares Emerging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
12/15/17
12/15
10:55
12/15/17
10:55
Conference/Events
Jefferies software/cybersecurity analyst holds analyst/industry conference call »

Analyst DiFucci, along…

CSCO

Cisco

$37.90

-0.25 (-0.66%)

, PANW

Palo Alto Networks

$147.38

1.95 (1.34%)

10:55
12/15/17
12/15
10:55
12/15/17
10:55
Conference/Events
Jefferies software/cybersecurity analyst holds analyst/industry conference call »

Analyst DiFucci, along…

CSCO

Cisco

$37.90

-0.25 (-0.66%)

PANW

Palo Alto Networks

$147.38

1.95 (1.34%)

SYMC

Symantec

$28.75

0.12 (0.42%)

CHKP

Check Point

$106.30

-0.13 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

  • 17

    Jan

  • 26

    Feb

ACHN

Achillion

10:51
12/15/17
12/15
10:51
12/15/17
10:51
Recommendations
Achillion analyst commentary  »

Achillion CMO departure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGP

Plains GP Holdings

$21.29

0.11 (0.52%)

10:50
12/15/17
12/15
10:50
12/15/17
10:50
Options
Notable option play in Plains GP as a position adjusted »

Notable option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:46
12/15/17
12/15
10:46
12/15/17
10:46
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

FCX

Freeport McMoRan

$16.64

0.45 (2.78%)

10:45
12/15/17
12/15
10:45
12/15/17
10:45
Options
Freeport McMoRan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
12/15/17
12/15
10:45
12/15/17
10:45
General news
Chicago Fed's Evans voted against the rate hike »

Chicago Fed's Evans…

TEVA

Teva

$18.42

1.116 (6.45%)

10:44
12/15/17
12/15
10:44
12/15/17
10:44
Upgrade
Teva rating change  »

Credit Suisse takes Teva…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$19.49

0.26 (1.35%)

, CS

Credit Suisse

$17.59

0.065 (0.37%)

10:44
12/15/17
12/15
10:44
12/15/17
10:44
Periodicals
U.S. judge dismisses $3B suit against Deutsche, Credit Suisse, Bloomberg says »

A U.S. judge has thrown…

DB

Deutsche Bank

$19.49

0.26 (1.35%)

CS

Credit Suisse

$17.59

0.065 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACHN

Achillion

10:40
12/15/17
12/15
10:40
12/15/17
10:40
Hot Stocks
Achillion reports resignation of Chief Medical Officer »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:39
12/15/17
12/15
10:39
12/15/17
10:39
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

TEVA

Teva

$18.39

1.08 (6.24%)

10:37
12/15/17
12/15
10:37
12/15/17
10:37
Upgrade
Teva rating change  »

Teva upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXRX

Concordia

$0.86

0.3261 (61.08%)

10:37
12/15/17
12/15
10:37
12/15/17
10:37
Hot Stocks
Concordia says 'unaware' of material change to account for market activity »

Concordia International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AU

AngloGold

$9.21

0.045 (0.49%)

10:35
12/15/17
12/15
10:35
12/15/17
10:35
Options
AngloGold put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.26

-0.025 (-0.47%)

10:35
12/15/17
12/15
10:35
12/15/17
10:35
Hot Stocks
AK Steel says UAW members ratify labor agreement for Dearborn Works »

AK Steel announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:30
12/15/17
12/15
10:30
12/15/17
10:30
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

NDSN

Nordson

$143.86

16.95 (13.36%)

10:27
12/15/17
12/15
10:27
12/15/17
10:27
Recommendations
Nordson analyst commentary  »

Nordson price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NMRK

Newmark

, BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

10:27
12/15/17
12/15
10:27
12/15/17
10:27
Syndicate
Breaking Syndicate news story on Newmark, BGC Partners »

Newmark indicated to open…

NMRK

Newmark

BGCP

BGC Partners

$15.23

-0.56 (-3.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 15

    Dec

10:25
12/15/17
12/15
10:25
12/15/17
10:25
General news
Treasury Action: Treasuries will remain in a bear-bull tug-o-war into 2018 »

Treasury Action:…

10:25
12/15/17
12/15
10:25
12/15/17
10:25
Conference/Events
JPMorgan household/personal product analyst has analyst/industry conference call »

Beverages, Household…

FOX

21st Century Fox

$34.22

1.88 (5.81%)

, FOXA

21st Century Fox

$34.88

2.13 (6.50%)

10:25
12/15/17
12/15
10:25
12/15/17
10:25
Conference/Events
FBN Securities media analyst to hold an analyst/industry conference call »

Cable, Media &…

FOX

21st Century Fox

$34.22

1.88 (5.81%)

FOXA

21st Century Fox

$34.88

2.13 (6.50%)

DIS

Disney

$110.93

0.36 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Dec

10:25
12/15/17
12/15
10:25
12/15/17
10:25
Conference/Events
JPMorgan insurance analyst has analyst/industry conference call »

Property & Casualty…

TEVA

Teva

$18.21

0.91 (5.26%)

10:24
12/15/17
12/15
10:24
12/15/17
10:24
Upgrade
Teva rating change  »

Teva upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.